Detecting intratumoral heterogeneity of EGFR activity by liposome-based in vivo transfection of a fluorescent biosensor.
Despite decades of research in the epidermal growth factor receptor (EGFR) signalling field, and many targeted anti-cancer drugs that have been tested clinically, the success rate for these agents in the clinic is low, particularly in terms of the improvement of overall survival. Intratumoral hetero...
| Egile Nagusiak: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formatua: | Journal article |
| Hizkuntza: | English |
| Argitaratua: |
2018
|
| _version_ | 1826268660292911104 |
|---|---|
| author | Weitsman, G Mitchell, NJ Evans, R Cheung, A Kalber, TL Bofinger, R Fruhwirth, GO Keppler, M Wright, ZVF Barber, PR Gordon, P de Koning, T Wulaningsih, W Vojnovic, B Ameer-Beg, S Lythgoe, M Arnold, JN Årstad, E Festy, F Hailes, HC Tabor, AB Ng, T |
| author_facet | Weitsman, G Mitchell, NJ Evans, R Cheung, A Kalber, TL Bofinger, R Fruhwirth, GO Keppler, M Wright, ZVF Barber, PR Gordon, P de Koning, T Wulaningsih, W Vojnovic, B Ameer-Beg, S Lythgoe, M Arnold, JN Årstad, E Festy, F Hailes, HC Tabor, AB Ng, T |
| author_sort | Weitsman, G |
| collection | OXFORD |
| description | Despite decades of research in the epidermal growth factor receptor (EGFR) signalling field, and many targeted anti-cancer drugs that have been tested clinically, the success rate for these agents in the clinic is low, particularly in terms of the improvement of overall survival. Intratumoral heterogeneity is proposed as a major mechanism underlying treatment failure of these molecule-targeted agents. Here we highlight the application of fluorescence lifetime microscopy (FLIM)-based biosensing to demonstrate intratumoral heterogeneity of EGFR activity. For sensing EGFR activity in cells, we used a genetically encoded CrkII-based biosensor which undergoes conformational changes upon tyrosine-221 phosphorylation by EGFR. We transfected this biosensor into EGFR-positive tumour cells using targeted lipopolyplexes bearing EGFR-binding peptides at their surfaces. In a murine model of basal-like breast cancer, we demonstrated a significant degree of intratumoral heterogeneity in EGFR activity, as well as the pharmacodynamic effect of a radionuclide-labeled EGFR inhibitor in situ. Furthermore, a significant correlation between high EGFR activity in tumour cells and macrophage-tumour cell proximity was found to in part account for the intratumoral heterogeneity in EGFR activity observed. The same effect of macrophage infiltrate on EGFR activation was also seen in a colorectal cancer xenograft. In contrast, a non-small cell lung cancer xenograft expressing a constitutively active EGFR conformational mutant exhibited macrophage proximity-independent EGFR activity. Our study validates the use of this methodology to monitor therapeutic response in terms of EGFR activity. In addition, we found iNOS gene induction in macrophages that are cultured in tumour cell-conditioned media as well as an iNOS activity-dependent increase in EGFR activity in tumour cells. These findings point towards an immune microenvironment-mediated regulation that gives rise to the observed intratumoral heterogeneity of EGFR signalling activity in tumour cells in vivo. |
| first_indexed | 2024-03-06T21:13:06Z |
| format | Journal article |
| id | oxford-uuid:3eda91f6-a25b-4bd4-bd4b-587a3809da2f |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T21:13:06Z |
| publishDate | 2018 |
| record_format | dspace |
| spelling | oxford-uuid:3eda91f6-a25b-4bd4-bd4b-587a3809da2f2022-03-26T14:28:15ZDetecting intratumoral heterogeneity of EGFR activity by liposome-based in vivo transfection of a fluorescent biosensor.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:3eda91f6-a25b-4bd4-bd4b-587a3809da2fEnglishSymplectic Elements at Oxford2018Weitsman, GMitchell, NJEvans, RCheung, AKalber, TLBofinger, RFruhwirth, GOKeppler, MWright, ZVFBarber, PRGordon, Pde Koning, TWulaningsih, WVojnovic, BAmeer-Beg, SLythgoe, MArnold, JNÅrstad, EFesty, FHailes, HCTabor, ABNg, TDespite decades of research in the epidermal growth factor receptor (EGFR) signalling field, and many targeted anti-cancer drugs that have been tested clinically, the success rate for these agents in the clinic is low, particularly in terms of the improvement of overall survival. Intratumoral heterogeneity is proposed as a major mechanism underlying treatment failure of these molecule-targeted agents. Here we highlight the application of fluorescence lifetime microscopy (FLIM)-based biosensing to demonstrate intratumoral heterogeneity of EGFR activity. For sensing EGFR activity in cells, we used a genetically encoded CrkII-based biosensor which undergoes conformational changes upon tyrosine-221 phosphorylation by EGFR. We transfected this biosensor into EGFR-positive tumour cells using targeted lipopolyplexes bearing EGFR-binding peptides at their surfaces. In a murine model of basal-like breast cancer, we demonstrated a significant degree of intratumoral heterogeneity in EGFR activity, as well as the pharmacodynamic effect of a radionuclide-labeled EGFR inhibitor in situ. Furthermore, a significant correlation between high EGFR activity in tumour cells and macrophage-tumour cell proximity was found to in part account for the intratumoral heterogeneity in EGFR activity observed. The same effect of macrophage infiltrate on EGFR activation was also seen in a colorectal cancer xenograft. In contrast, a non-small cell lung cancer xenograft expressing a constitutively active EGFR conformational mutant exhibited macrophage proximity-independent EGFR activity. Our study validates the use of this methodology to monitor therapeutic response in terms of EGFR activity. In addition, we found iNOS gene induction in macrophages that are cultured in tumour cell-conditioned media as well as an iNOS activity-dependent increase in EGFR activity in tumour cells. These findings point towards an immune microenvironment-mediated regulation that gives rise to the observed intratumoral heterogeneity of EGFR signalling activity in tumour cells in vivo. |
| spellingShingle | Weitsman, G Mitchell, NJ Evans, R Cheung, A Kalber, TL Bofinger, R Fruhwirth, GO Keppler, M Wright, ZVF Barber, PR Gordon, P de Koning, T Wulaningsih, W Vojnovic, B Ameer-Beg, S Lythgoe, M Arnold, JN Årstad, E Festy, F Hailes, HC Tabor, AB Ng, T Detecting intratumoral heterogeneity of EGFR activity by liposome-based in vivo transfection of a fluorescent biosensor. |
| title | Detecting intratumoral heterogeneity of EGFR activity by liposome-based in vivo transfection of a fluorescent biosensor. |
| title_full | Detecting intratumoral heterogeneity of EGFR activity by liposome-based in vivo transfection of a fluorescent biosensor. |
| title_fullStr | Detecting intratumoral heterogeneity of EGFR activity by liposome-based in vivo transfection of a fluorescent biosensor. |
| title_full_unstemmed | Detecting intratumoral heterogeneity of EGFR activity by liposome-based in vivo transfection of a fluorescent biosensor. |
| title_short | Detecting intratumoral heterogeneity of EGFR activity by liposome-based in vivo transfection of a fluorescent biosensor. |
| title_sort | detecting intratumoral heterogeneity of egfr activity by liposome based in vivo transfection of a fluorescent biosensor |
| work_keys_str_mv | AT weitsmang detectingintratumoralheterogeneityofegfractivitybyliposomebasedinvivotransfectionofafluorescentbiosensor AT mitchellnj detectingintratumoralheterogeneityofegfractivitybyliposomebasedinvivotransfectionofafluorescentbiosensor AT evansr detectingintratumoralheterogeneityofegfractivitybyliposomebasedinvivotransfectionofafluorescentbiosensor AT cheunga detectingintratumoralheterogeneityofegfractivitybyliposomebasedinvivotransfectionofafluorescentbiosensor AT kalbertl detectingintratumoralheterogeneityofegfractivitybyliposomebasedinvivotransfectionofafluorescentbiosensor AT bofingerr detectingintratumoralheterogeneityofegfractivitybyliposomebasedinvivotransfectionofafluorescentbiosensor AT fruhwirthgo detectingintratumoralheterogeneityofegfractivitybyliposomebasedinvivotransfectionofafluorescentbiosensor AT kepplerm detectingintratumoralheterogeneityofegfractivitybyliposomebasedinvivotransfectionofafluorescentbiosensor AT wrightzvf detectingintratumoralheterogeneityofegfractivitybyliposomebasedinvivotransfectionofafluorescentbiosensor AT barberpr detectingintratumoralheterogeneityofegfractivitybyliposomebasedinvivotransfectionofafluorescentbiosensor AT gordonp detectingintratumoralheterogeneityofegfractivitybyliposomebasedinvivotransfectionofafluorescentbiosensor AT dekoningt detectingintratumoralheterogeneityofegfractivitybyliposomebasedinvivotransfectionofafluorescentbiosensor AT wulaningsihw detectingintratumoralheterogeneityofegfractivitybyliposomebasedinvivotransfectionofafluorescentbiosensor AT vojnovicb detectingintratumoralheterogeneityofegfractivitybyliposomebasedinvivotransfectionofafluorescentbiosensor AT ameerbegs detectingintratumoralheterogeneityofegfractivitybyliposomebasedinvivotransfectionofafluorescentbiosensor AT lythgoem detectingintratumoralheterogeneityofegfractivitybyliposomebasedinvivotransfectionofafluorescentbiosensor AT arnoldjn detectingintratumoralheterogeneityofegfractivitybyliposomebasedinvivotransfectionofafluorescentbiosensor AT arstade detectingintratumoralheterogeneityofegfractivitybyliposomebasedinvivotransfectionofafluorescentbiosensor AT festyf detectingintratumoralheterogeneityofegfractivitybyliposomebasedinvivotransfectionofafluorescentbiosensor AT haileshc detectingintratumoralheterogeneityofegfractivitybyliposomebasedinvivotransfectionofafluorescentbiosensor AT taborab detectingintratumoralheterogeneityofegfractivitybyliposomebasedinvivotransfectionofafluorescentbiosensor AT ngt detectingintratumoralheterogeneityofegfractivitybyliposomebasedinvivotransfectionofafluorescentbiosensor |